SAN DIEGO, March 6 /PRNewswire-FirstCall/ -- SpectraScience, Inc. announced today that it has negotiated a distribution agreement with a newly formed organization to sell its products in Europe. The company, SpectraScience Endoscopy EU (SSEEU), is a well-financed consortium of individuals with extensive experience in medical device markets.
Jim Hitchin the Company’s CEO said, “This agreement is the first step in our goal to fully commercialize the WavSTAT(TM) cancer screening device. SSEEU has incredible resources and experience in developing a market for new devices. We look forward to a very rewarding future with them to develop the market with Gastrointerologists for our patented and proprietary WavSTAT(TM) Optical Biopsy System.”
The WavSTAT(TM) is used by physicians to diagnose tissue to determine if it is normal, pre-cancerous, or cancerous within one second. The WavSTAT(TM) System is currently approved by the FDA for use in detecting cancer in the colon. A new application for detecting pre-cancers in the throat, sometimes called Barrett’s esophagus, is being tested in a clinical trial. Cancer of the esophagus is more than 90% fatal and may develop as a result of chronic heartburn or GERD. Esophageal cancer is growing five times faster than all other cancers.”
This news release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience’s actual results to differ materially from the results discussed in the forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, the Form 10-KSB and in SpectraScience’s other reports filed with the Securities and Exchange Commission (“SEC”) that attempt to advise interested parties of the risks and factors that may affect SpectraScience’s business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-KSB and other documents.
For further information contact Jim Hitchin at (858) 847-0200 x 201. http://www.spectrascience.com
SpectraScience, Inc.
CONTACT: Jim Hitchin of SpectraScience, Inc., +1-858-847-0200, ext. 201
Web site: http://www.spectrascience.com//
